We already have one thats on the market, tirzepatide (Mounjaro), which is activating both the GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, and at least in terms of weight loss, appears to be somewhat more effective than semaglutide (Ozempic), says Professor Cummings
Your doctor may recommend gradually reducing your dosage if discontinuation is necessary
Anecdotal community reports typically describe 1030mg per day taken orally, with 10mg being a common starting point
Compare this compound $50 CAD
Anesthetists should be given specific GLP-1 last dose dates, type (short-acting vs long-acting), and recent hypoglycemia or GI effects
and see how they respond before eating or drinking more